Insider Buying: DENTSPLY SIRONA (NASDAQ:XRAY) Director Acquires 15,175 Shares of Stock

Posted by on Jun 15th, 2026

DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Get Free Report) Director Michael Barber bought 15,175 shares of the stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $9.88 per share, with a total value of $149,929.00. Following the completion of the purchase, the director directly owned 55,943 shares of the company’s stock, valued at approximately $552,716.84. This represents a 37.22% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

DENTSPLY SIRONA Stock Up 0.5%

Shares of DENTSPLY SIRONA stock traded up $0.05 during trading hours on Monday, hitting $10.14. 2,935,013 shares of the company’s stock traded hands, compared to its average volume of 4,807,656. The stock has a 50 day simple moving average of $10.98 and a 200-day simple moving average of $11.71. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. The company has a market cap of $2.03 billion, a PE ratio of -3.22, a PEG ratio of 1.20 and a beta of 0.89. DENTSPLY SIRONA Inc. has a twelve month low of $9.40 and a twelve month high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). The business had revenue of $880.00 million for the quarter, compared to analyst estimates of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm’s revenue was up .1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Barrington Research raised their target price on DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a research note on Monday, March 2nd. Barclays decreased their price target on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a research note on Thursday, June 4th. Wells Fargo & Company lifted their price target on DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Mizuho decreased their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, Weiss Ratings downgraded DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, DENTSPLY SIRONA currently has a consensus rating of “Hold” and a consensus target price of $13.55.

Check Out Our Latest Analysis on DENTSPLY SIRONA

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in DENTSPLY SIRONA by 4.1% in the third quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier’s stock worth $279,263,000 after acquiring an additional 869,566 shares during the last quarter. First Eagle Investment Management LLC raised its holdings in shares of DENTSPLY SIRONA by 3.2% during the fourth quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock valued at $167,342,000 after buying an additional 458,744 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of DENTSPLY SIRONA by 109.8% during the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after buying an additional 6,970,086 shares during the last quarter. Lazard Asset Management LLC raised its holdings in shares of DENTSPLY SIRONA by 0.9% during the third quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock valued at $129,445,000 after buying an additional 92,868 shares during the last quarter. Finally, Southpoint Capital Advisors LP bought a new stake in shares of DENTSPLY SIRONA during the first quarter valued at approximately $116,000,000. Institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

(Get Free Report)

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

See Also

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.